Article

Women and Minorities Under-Treated for Stroke

Author(s):

“Even though the treatment for stroke tPA improves recovery, some people who are eligible to receive the treatment are not getting it,” study author, Steven R. Messé, MD, explained.

Women and minorities are less likely to receive the clot busting intravenous stroke treatment tissue plasminogen activator (tPA), according to findings published in Neurology.

Researchers from the University of Pennsylvania retrospectively analyzed more than 60,000 patients over eight years with acute ischemic stroke in order to determine patient and hospital characteristics linked to not providing tPA to eligible patients in clinical practice. The patients arrived to hospital settings within two hours of experiencing stroke symptoms. The researchers also noted the patients presented no documented reasons they could not receive tPA.

A quarter of the patients did not receive tPA within three hours of arriving to the hospital, the researchers learned, but they did add that treatment rates improved as years passed. About half of the eligible patients received tPA between 2003 and 2005 compared to 82% between 2010 and 2011.

Some of the reasons for treatment failure included stroke severity, factors linked to older age, female sex, nonwhite race, diabetes mellitus, prior stroke, atrial fibrillation, prosthetic heart valve, NIH Stroke Scale score <5, arrival during off hours and not via emergency medical services, longer onset to arrival and door to CT scan times, earlier in the calendar year, and arrival at a rural, non teaching, not stroke center hospital located in the south or Midwest areas of the United States.

“Even though the treatment for stroke tPA improves recovery, some people who are eligible to receive the treatment are not getting it,” study author, Steven R. Messé, MD, explained in a press release. “We wanted to find out what factors were associated with lower likelihood of treatment, which may help us find ways to improve tPA use in the future. More research is needed about why these potential disparities exist and how they can be addressed."

Related Coverage:

Questioning Warfarin Use in Patients with End-Stage Renal Disease

Women's Risk of Stroke, and Type of Stroke, Influenced by BMI

Preventive Stroke Device Gets FDA Approval

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.